Onco-Innovations Announces Non-Brokered LIFE Offering

Executive Summary

• Onco-Innovations Limited announced its intention to complete a non-brokered private placement of 6,764,069 units at CAD$0.7392 per unit, targeting approximately CAD$5,000,000 in aggregate gross proceeds.
• Each unit consists of one common share and one warrant exercisable at CAD$0.90 per share for a three-year term, with an acceleration clause triggered if the share price reaches CAD$1.30.
• Net proceeds will be directed toward advancing the clinical development of the ONC010 program, funding SynoGraph™ platform activities, and supporting general working capital and corporate purposes.

Key Details

• Transaction Structure: Non-brokered private placement offered under the Listed Issuer Financing Exemption (NI 45-106 Part 5A).
• Quantity & Price: 6,764,069 Units offered at CAD$0.7392 per Unit.
• Gross Proceeds: Approximately CAD$5,000,000.
• Unit Composition: Each Unit comprises one common share and one common share purchase warrant.
• Warrant Terms: Warrants are exercisable at CAD$0.90 per share for a period of three years following the closing date.
• Warrant Acceleration Clause: If the 10-day volume-weighted average trading price (VWAP) on the Cboe equals or exceeds CAD$1.30 at the close of any trading day, the Company may accelerate the warrant expiry date by issuing a news release, making the expiry date 30 days following that release.
• Closing Date & Conditions: Expected to close on or about July 10, 2026, subject to receiving subscriptions for at least 6,764,069 Units and obtaining all necessary regulatory approvals, including from Cboe Canada Inc.
• Minimum Subscription Requirement: The placement will not close unless subscriptions for at least 6,764,069 Units are received; otherwise, all subscription funds will be returned to investors.
• Use of Proceeds: Advancing the ONC010 program through key clinical development stages (including manufacturing and preclinical testing), developing the SynoGraph™ platform, and general working capital/corporate purposes.
• Regulatory & Distribution: Offered to purchasers resident in all Canadian provinces except Quebec and certain offshore purchasers. Units are not subject to a hold period under applicable Canadian securities laws. Offering documents are available on SEDAR+ and the Company’s website.